Navigation Links
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Date:8/4/2011

CRANBURY, N.J., Aug. 4, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate selected by AstraZeneca from its collaborative research program with Palatin Technologies.

Obesity is a global problem, with the World Health Organization estimating that over 1.5 billion adults are overweight and over 500 million are obese. Worldwide obesity has more than doubled since 1980.  A number of different metabolic and hormonal pathways are being evaluated by companies around the world in efforts to develop better treatments for obesity. Scientific research has established that melanocortin receptors have a role in eating behavior and energy homeostasis, and that some melanocortin receptor agonists decrease food intake and induce weight loss in animal studies.

The single center study is expected to enroll 90 subjects in a randomized, single-blind, placebo-controlled, Phase 1 trial in healthy male volunteers. For more information on this clinical trial with AZD2820, please visit www.clinicaltrials.gov .

"We are very pleased that AstraZeneca has initiated a Phase 1 clinical trial with a collaboration compound, demonstrating AstraZeneca's ongoing commitment and diligence in exploring melanocortin compounds for the treatment of obesity," said Dr. Carl Spana, President and Chief Executive Officer of Palatin.

Pursuant to the terms of the research collaboration and license agreement with AstraZeneca, Palatin is eligible for milestone payments upon achieving development and regulatory milestones and further payments on achievement of sales targets, in addition to roy
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies, Inc. Announces Presentation and Publication on Validation of Scale for Subjective Male Sexual Arousal
2. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
3. Palatin Technologies, Inc. Announces Results of Annual Stockholders Meeting
4. Palatin Technologies, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference
5. Palatin Technologies, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants
7. Palatin Technologies, Inc. December 31, 2010 Quarter Results; Teleconference and Webcast to be Held on February 24, 2011
8. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2011 Results
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Palatin Announces Strategic Realignment of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... SEOUL, South Korea , March 4, 2015 /PRNewswire/ ... based biopesticide company, in August of last year. As ... with Kyung Bon Koo continuing his role ... Selakovic , President of Vegalab S.A., will work alongside ... Photo - http://photos.prnewswire.com/prnh/20150303/179218 ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ) ... Market, 2015 - 2025" report to their offering. ... provides an extensive study on the marketed and pipeline ... out in this field for over a decade but ... Asian markets; one approved in the EU). There are ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 Crown Bioscience, ... company, has launched a new Life Science division specializing ... preclinical research. , The first products released include ... controls, and soon to be released in vivo grade ... continue to expand their life science portfolio with additional ...
Breaking Biology Technology:Korean Government Program Supports Vegalab's Research and Development 2Korean Government Program Supports Vegalab's Research and Development 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2
... has closed a public offering of three million ... million for general corporate purposes. , ,The company announced ... $3.75 per share, marketed to institutional investors following a ... Exchange Commission . , ,Sonic Foundry, which develops a ...
... , a Grand Rapids-based provider of data bandwidth capacity, will ... in metropolitan Milwaukee. , ,The company, which serves Midwestern enterprise ... 31 of this year. , ,US Signal's network deployment ... Milwaukee and powered by the Cisco optical platform. ...
... Madison, Wis. - Third Wave Technologies, Inc ., ... to the U.S. Food and Drug Administration for approval of ... test product, which Third Wave calls InPlex, is a genotyping ... to aid in newborn screening and in diagnostic testing in ...
Cached Biology Technology:
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... 15, 2015  BellBrook Labs, a leader in high ... launch of a TR-FRET (time resolved Forster resonance ... Assay, a high throughput screening assay for glycosyltransferases ... allow for sensitive detection of hundreds of human ...
(Date:1/22/2015)... (NASDAQ: NXTD and NXTDW) a biometric authentication company focused ... the Wocket™ smart wallet at CES 2015 in Las Vegas ... of the "11 Hot Products at CES" in a review published in ... by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... of choice when it comes to the types of fat cells in ... it. The danger in white fat cells, along with the increased risk ... fat. Visceral fat is the build-up of fat around the organs in ... fat appears to be our friend and white fat our foe. ...
... FL (May 6, 2012) There may be new ... medicine injected directly into the eyes fails to cause ... called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered a modern miracle ... with the fast-progressive form of macular degeneration, they are ...
... in German . Halle/Saale. In order to ... These differ in part considerably from the propagation strategies of ... Knapp of the Helmholtz Centre for Environmental Research (UFZ) reached ... of the scientific journal Ecology Letters . "These results ...
Cached Biology News:A new candidate pathway for treating visceral obesity 2First oral agent to quell invasive macular degeneration, restore lost vision 2First oral agent to quell invasive macular degeneration, restore lost vision 3Different recipes for success in the world of plants 2Different recipes for success in the world of plants 3
...
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... offers single pass sequencing of plasmids ... fueled by our high performance sequencing ... Phred20 bases per day. The key ... sequencing customers are rapid turnaround, high ...
... Agencourt offers a high quality whole genome ... while reducing costs allow even the smallest ... endeavors. The key features which set our ... unique library construction strategies, proprietary assembly software, ...
Biology Products: